Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

310.55
Delayed Data
As of Sep 28
 -3.98 / -1.27%
Today’s Change
223.02
Today|||52-Week Range
333.65
+1.37%
Year-to-Date
Why Anavex Life Sciences Corp. Rocketed Higher Today
Sep 28 / MotleyFool.com - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Instant Analysis: Biogen's Agreement With Anavex Life Sciences
Sep 28 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD ...
Sep 21 / Zacks.com - Paid Partner Content
Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?
Sep 28 / MotleyFool.com - Paid Partner Content
3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition
Sep 19 / MotleyFool.com - Paid Partner Content
Ionis/Biogen Complete Nusinersen NDA Submission in U.S.
Sep 27 / Zacks.com - Paid Partner Content
Could This Alzheimers Disease Drug Really Be Worth $20 Billion?
Sep 19 / MotleyFool.com - Paid Partner Content
Health Care Stocks Bound for Declines After 2016 Election
Sep 22 / TheStreet.com - Paid Partner Content
Marijuana Could Be the Answer to Curing Alzheimer's Disease, Study Shows
Sep 18 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close314.53
Today’s open315.99
Day’s range308.74 - 315.99
Volume1,020,123
Average volume (3 months)1,883,015
Market cap$68.9B
Dividend yield--
Data as of 3:59pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+16.59%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)-3.87%
P/E ratio18.1
Price/Sales7.60
Price/Book7.34

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences-0.28-0.35%
ILMNIllumina Inc+0.63+0.35%
AMGNAmgen-1.92-1.12%
NBIXNeurocrine Bioscienc...-1.94-3.64%
Data as of 4:14pm ET, 09/28/2016

Financials

Next reporting dateOctober 26, 2016
EPS forecast (this quarter)$5.02
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Search for Jobs